Orion Corporation

Incorporated in 1917, the company headquartered in Espoo, Finland, operates predominantly in the pharmaceuticals industry with a diversified portfolio including veterinary medicine, proprietary and generic drugs, and the manufacturing of active pharmaceutical ingredients. The company demonstrates a strong emphasis on certain business segments that have positioned it effectively within the market. The company's notable brands reflect its focus and expertise in its key business categories. The Easyhaler brand has gained significant traction in the respiratory disease market, while Dexdor is a staple in the realm of intensive care sedation. Simdax is recognized for its application in treating acute heart failure, another testament to the company's medical range. In the oncology sector, Nubeqa marks its presence as a treatment for prostate cancer, the result of a strategic licensing partnership with Bayer. Additionally, the brand Fermion showcases the company's capability in the production of active pharmaceutical ingredients, emphasizing its role in both the B2B and B2C market segments. The company's footprint extends well beyond its headquarters, with a major presence in Europe where it commands strong sales. Beyond the continent, the company's products are also available worldwide, reaching markets such as Russia. Furthermore, through dynamic partnerships and licensing agreements, its products have penetrated the North American and Asian markets, highlighting its global distribution capabilities and the universal applicability of its pharmaceutical expertise. (Powered by AI)